Here's how much weight loss drugs could cost you under Trump's deals with Eli Lilly, Novo Nordisk

President Trump has secured landmark deals with Eli Lilly and Novo Nordisk to substantially reduce the prices of their blockbuster GLP-1 weight loss drugs, significantly expanding market access. Under these agreements, patient out-of-pocket costs could fall to $50-$350 monthly, down from over $1,000, and Medicare will begin covering obesity GLP-1s for eligible patients by mid-2026 at a $50 copay, with the government price set at $245 per month. The deals also establish lower pricing on direct-to-consumer platforms and for Medicaid, while granting fast-track reviews for the companies' forthcoming oral GLP-1 treatments. This initiative represents a major shift in the accessibility and pricing landscape for these high-demand pharmaceuticals, potentially increasing volume but impacting per-unit revenue and accelerating new product launches.

Analysis

President Trump's landmark deals with Eli Lilly and Novo Nordisk significantly reduce the out-of-pocket cost for blockbuster GLP-1 weight loss drugs, potentially ranging from $50 to $350 monthly, a substantial decrease from current list prices exceeding $1,000. This initiative, under a "most favored nation" policy, aims to dramatically expand patient access through various channels, including direct-to-consumer platforms like TrumpRx, where injectables will average $350, dropping to $250.

A pivotal aspect of the agreement is Medicare's unprecedented coverage of GLP-1s for obesity starting mid-2026, with eligible patients facing a $50 monthly copay and the government price set at $245 per month for non-starting doses. This expansion targets specific cohorts based on BMI and co-morbidities, while lower government pricing of $245 per month is also extended to all 50 Medicaid programs, contingent on state opt-in.

For Eli Lilly (LLY) and Novo Nordisk (NVO), these agreements balance increased market penetration and volume against lower per-unit revenue. The deals also include fast-track reviews for their forthcoming oral GLP-1 pills, suggesting an accelerated path to market for these potentially transformative treatments. The overall sentiment surrounding these developments is strongly positive for both companies, indicating market optimism regarding the long-term growth potential despite pricing adjustments.

Key Decisions for Investors

• Investors should closely monitor the net revenue impact for Eli Lilly and Novo Nordisk, weighing the substantial increase in GLP-1 prescription volumes against the agreed-upon lower pricing across Medicare, Medicaid, and DTC channels.
• Track the progress and approval timelines of oral GLP-1 treatments from both companies, as fast-track reviews could accelerate market entry and further expand the addressable patient population.
• Evaluate the rate of Medicare patient eligibility and state Medicaid opt-ins for GLP-1 coverage, as these factors will be critical indicators of the ultimate market expansion and revenue growth for the pharmaceutical firms.